Research News for June 2010
11–17 of 17 articles
-
Adding Avastin to Chemo Stops Metastatic Cancer From Growing
Adding Avastin to any of several common chemotherapy regimens for metastatic, HER2-negative breast cancer seems to lengthen the time before the cancer grows compared to the same regimen without Avastin.
-
Experimental Combo Shows Promise for Treating Metastatic HER2-Positive Cancer
A very small, very early study suggests that a combination of Herceptin and Afinitor may help treat HER2-positive, metastatic breast cancers that have stopped responding to many other treatments.
-
Eribulin May Be Treatment Option for Metastatic Breast Cancer
Research suggests that eribulin, an experimental chemotherapy medicine, may be a good treatment option for metastatic breast cancer that has stopped responding to other treatments.
-
Intraoperative Radiation May Work as Well as Standard Delivery Method
Research suggests that intraoperative radiation therapy and traditional external beam radiation are equally effective and safe.
-
Retesting Metastatic Cancer’s HER2 Status Can Predict Response to Experimental Medicine
Retesting metastatic breast cancer for HER2 status -- to see if the cancer is still HER2-positive -- can help figure out if the cancer is more or less likely to respond to T-DM1, an experimental targeted therapy medicine.
-
Prolia Approved to Treat Osteoporosis
A new osteoporosis treatment called Prolia has been approved by the U.S. Food and Drug Administration.
-
Giving Chemo Medicines Sequentially May Have Advantages
Treating early-stage breast cancer with two chemotherapy medicines followed by a third seems to have some advantages compared to giving two or three medicines at the same time, but may cause more severe side effects.
11–17 of 17 articles
